The EMA has said it will fast-track the review of Gilead Sciences’ remdesivir as a treatment for COVID-19, after the US biopharma submitted its marketing application for the dr
COVID-19 has left no part of life untouched, including health technology assessment (HTA) and other payer agency activities, and it will likely have a lasting impact on market access.
Almost exactly six years ago AstraZeneca managed to convince investors to reject a takeover bid from Pfizer – and now the UK pharma is reportedly planning its own mega-merger with Gilead. <
With most of the world being in lockdown we are all looking for new ways to continue to lead our lives as normally as possible, from personal Zoom quiz nights with family to gathering marke
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.